Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
24-month Randomized, Double-masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.
Sponsor: Novartis
Terminated
Study was terminated based on the results of analyses performed as planned at Month 12.
Other terminated trials from Novartis
Other Choroidal Neovascularization trials with similar outcome
This PHASE2/PHASE3 trial investigates Choroidal Neovascularization and Macular Degeneration and is currently terminated or withdrawn. Novartis leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Antwerp, Belgium , Budapest, Hungary , Créteil, France , Florence, Italy , Geneva, Switzerland , Madrid, Spain , Manchester, United Kingdom , Regensburg, Germany , Rotterdam, Netherlands and 2 more locations